Modelling Ponatinib Resistance in Tyrosine Kinase Inhibitor-Naïve and Dasatinib Resistant BCR-ABL1+ Cell Lines

Oncotarget - United States
doi 10.18632/oncotarget.26187
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia

Molecular Therapy - Nucleic Acids
Drug DiscoveryMolecular Medicine
2017English

Tyrosine Kinase Fusion Genes in Pediatric BCR-ABL1-like Acute Lymphoblastic Leukemia

Oncotarget
Oncology
2016English

The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients With Chronic Myeloid Leukemia

Cancer
Cancer ResearchOncology
2018English

Differential Genomics and Transcriptomics Between Tyrosine Kinase Inhibitor-Sensitive and -Resistant BCR-ABL-dependent Chronic Myeloid Leukemia

Oncotarget
Oncology
2018English

Genetic Alterations in Epidermal Growth Factor Receptor‑tyrosine Kinase Inhibitor‑na�ve Non‑small Cell Lung Carcinoma

Oncology Letters
Cancer ResearchOncology
2020English

BCR-ABL Tyrosine Kinase

Science-Business eXchange
2012English

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

Frontiers in Cardiovascular Medicine
Cardiovascular MedicineCardiology
2018English

BCR-ABL1 and Beyond

Pathology
Forensic MedicinePathology
2020English

The Tyrosine Kinase Inhibitor Dasatinib Reduces the Growth of Intracellular Mycobacterium Tuberculosis Despite Impairing T-Cell Function

European Journal of Immunology
AllergyImmunology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy